Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;2003(2):CD003580.
doi: 10.1002/14651858.CD003580.

Heparin for pregnant women with acquired or inherited thrombophilias

M C Walker  1 , S E Ferguson, V M Allen
Affiliations

Heparin for pregnant women with acquired or inherited thrombophilias

M C Walker et al. Cochrane Database Syst Rev. 2003.

Abstract

Background: Thrombophilias, which are associated with a predisposition to thrombotic events, have been implicated in adverse obstetrical outcomes such as intrauterine growth restriction, stillbirth, severe early onset pre-eclampsia, and placental abruption. Heparin administration in pregnancy may reduce the risk of these events.

Objectives: The objective of this review was to assess the effects of heparin on pregnancy outcomes for women with a thrombophilia.

Search strategy: We searched the Cochrane Pregnancy and Childbirth Group trials register (July 2002), MEDLINE, EMBASE, CINAHL, Scidex (via OVID Technologies - July 2002) and reference lists and personal files.

Selection criteria: Randomized controlled trials comparing heparin with placebo or no treatment, or randomized controlled trials comparing any two treatments. Quasi randomized studies would be included.

Data collection and analysis: Data would be abstracted from identified studies and recorded on a paper form by two reviewers.

Main results: No studies were included.

Reviewer's conclusions: There are no completed trials to determine the effects of heparin on pregnancy outcomes for women with a thrombophilia.

PubMed Disclaimer

Conflict of interest statement

None known.

References

References to studies awaiting assessment

Abou‐Nassar 2006 {published data only}
    1. Abou‐Nassar K, Rodger M, Kovacs MJ, Doucette S, Tim R, Kahn S, et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial. Blood 2006;108(11 Pt 1):262. - PubMed
Abou‐Nassar 2007 {published data only}
    1. Abou‐Nassar K, Kovacs MJ, Kahn SR, Wells P, Doucette S, Ramsay T, et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thrombosis and Haemostasis 2007;98(1):163‐71. - PubMed
Brenner 2002 {published data only}
    1. Brenner B, for theLIVE‐ENOXI. Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss. The LIVE‐ENOX study [abstract]. Blood 2002;100(11 Pt 1):702a. - PubMed
Brenner 2003 {published data only}
    1. Brenner B, Hoffman R, Carp H, Dulitsky M, Samueloff A, Yohai D, et al. Enoxaparin treatment improves the gestational outcome of pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE‐ENOX study [abstract]. Blood 2003;102(11):16a.
Brenner 2003a {published data only}
    1. Brenner B, Hoffman R, Carp H, Dulitsky M, Samueloff A, Yohal D, et al. Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE‐ENOX study [abstract]. Journal of Thrombosis and Haemostasis 2003;1(Suppl 1):OC084. - PubMed
Brenner 2005 {published data only}
    1. Brenner B, Bar J, Ellis M, Yarom I, Yohai D, Samueloff A, et al. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the live‐enox study. Fertility & Sterility 2005;84(3):770‐3. - PubMed
Brenner 2005a {published data only}
    1. Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J, LIVE‐ENOX I. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the live‐enox study [See comment]. Journal of Thrombosis & Haemostasis 2005;3(2):227‐9. - PubMed
Casele 2005 {published data only}
    1. Casele H. Thrombosis prophylaxis in pregnancy (ongoing). Evanston Northwestern Healthcare (www.enh.org) (accessed 14 June 2005) 2005.
Chistolini 2006 {published data only}
    1. Chistolini A, Torelli F, Giancotti A, Pignoloni P, Muto B, Cosimo C, et al. Recurrent fetal loss: prospective evaluation of the efficacy of three different thromboprophylaxis regimens: aspirin versus low molecular weight heparin versus low molecular weight heparin plus aspirin [abstract]. Hematology Journal 2006;91(Suppl 1):146.
Clemens 2011 {published data only}
    1. Clemens B. Heparin for pregnant women with thrombophilia. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 15 February 2011) 2011.
Dendrinos 2007 {published data only}
    1. Dendrinos S, Kalogirou I, Makrakis E, Theodoridis T, Mahmound EA, Christopoulou‐Cokkinou V, et al. Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss. Clinical and Experimental Obstetrics and Gynecology 2007;34(3):143‐5. - PubMed
de Vries 2011 {published data only}
    1. Vries J, Pampus MG, Hague WM, Bezemer PD, Joosten JH. Fractionated heparin in pregnant women with a history of uteroplacental insuffi ciency and thrombophilia, a randomized trial (The FRUIT Study). Reproductive Sciences 2011;18(3 Suppl 1):69A.
Gates 2004 {published data only}
    1. Gates S, Brocklehurst P, Ayers S, Bowler U. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low‐molecular‐weight heparin. American Journal of Obstetrics and Gynecology 2004;191:1296‐303. - PubMed
Kamin 2008 {published data only}
    1. Kamin G, Rogenhofer N, Pildner v. Steinberg S, Neuhoffer A, Seeger S, Schleussner E. Therapy with dalteparin for habitual abortion ‐ presentation of the ETHiG II‐Studie [Therapie mit Dalteparin bei habitueller Abortneigung ‐ Vorstellung der ETHiG II‐Studie]. Geburtshilfe und Frauenheilkunde 2008;68:S51.
Laskin 2009 {published data only}
    1. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. Journal of Rheumatology 2009;36(2):279‐87. - PubMed
Rodger 2005 {published data only}
    1. Rodger MA, Lazo‐Langner A, Kahn S, Kovacs M, Robinson S, Blostein M, et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy. Blood 2005;106(11):Abstract no 548.
Rodger 2006 {published data only}
    1. Rodger MA, Kahn S, Cranney A, Hodson A, Kovacs M, Clement AM, et al. Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]. Hypertension in Pregnancy 2006;25(Suppl 1):8.
Rodger 2007 {published data only}
    1. Rodger MA, Kahn SR, Cranney A, Hodsman A, Kovacs MJ, Clement AM, et al. Long‐term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis 2007;5(8):1600‐6. - PubMed
Rodger 2011 {published data only}
    1. Rodger MA. PROSPER: Postpartum prophylaxis for PE randomized control trial pilot. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 15 February 2011) 2011.
Tempfer 2012 {published data only}
    1. Tempfer CB. Heparin for pregnant with thrombophilia. http://clinicaltrials.gov/show/NCT01019655 (accessed 29 July 2012).
Thaler 2004 {published data only}
    1. Thaler I, Brenner B. Efficacy of enoxaparin for improving pregnancy outcomes and uteroplacental blood flow in women with thrombophilia and recurrent pregnancy loss [abstract]. American Journal of Obstetrics and Gynecology 2004;191(6 Suppl 1):S7.
Visser 2009 {published data only}
    1. Visser J, Ulander V, Bloemenkamp K, Kaaja R. A randomised controlled multicenter study: the effect of enoxaparin and/or aspirin on prevention of recurrent miscarriage in women with or without thrombophilia, HABENOX‐study. International Journal of Gynecology & Obstetrics 2009;107(Suppl 2):S371.
Visser 2011 {published data only}
    1. Visser J, Ulander VM, Helmerhorst FM, Lampinen K, Morin‐Papunen L, Bloemenkamp KWM, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia ‐ HABENOX*: a randomised multicentre trial. Thrombosis and Haemostasis 2011;105(2):295‐301. - PubMed

References to ongoing studies

de Vries 2000 {unpublished data only}
    1. de Vries. Low Molecular weight heparin (FRagmin) in pregnant women with a history of Uteroplacental Insufficiency and Thrombophilia (The Fruit Study). Personal communication 2000.
Rodgers 2000 {unpublished data only}
    1. Rodgers M. Thrombophilia in Pregnancy Prophylaxis Study (TIPPS). Personal communication 2000.

Additional references

de Vries 1997
    1. Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, Geijn HP. Hyperhomocysteinaemia and protein s deficiency in complicated pregnancies. British Journal of Obstetrics and Gynaecology 1997;104(11):1248‐54. - PubMed
Dekker 1995
    1. Dekker GA, Vries J, Doelitzsch MS, Huijgens PC, Blomberg B, Jakobs C, et al. Underlying disorders with severe early‐onset preeclampsia. American Journal of Obstetrics and Gynecology 1995;173(4):1042‐8. - PubMed
Dizon‐Townson 1996
    1. Dizon‐Townson DS, Nelson LM, Easton K, Ward K. The factor v leiden mutation may predispose women to severe preeclampsia. American Journal of Obstetrics and Gynecology 1996;175(4 Pt 1):902‐5. - PubMed
Dizon‐Townson 1997
    1. Dizon‐Townson DS, Meline L, Nelson LM, Varner M, Ward K. Fetal carriers of the factor v leiden mutation are prone to miscarriage and placental infarction. American Journal of Obstetrics and Gynecology 1997;177(2):402‐5. - PubMed
Goddijn‐Wessel 1996
    1. Goddijn‐Wessel TA, Wooters MG, Molen EF, Spuijbroek MD, Steegers‐Theunissen RP, Blom HJ, et al. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. European Journal of Obstetrics, Gynecology and Reproductive Biology 1996;66:23‐9. - PubMed
Kahn 1998
    1. Kahn SR. Severe preeclampsia associated with coinheritance of factor v leiden mutation and protein S deficiency. Obstetrics and Gynecology 1998;91(5 Pt 2):812‐4. - PubMed
Krauss 1998
    1. Krauss T, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn W. Activated protein c resistance and factor v leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstetrics and Gynecology 1998;92(3):457‐60. - PubMed
Kupferminc 1999
    1. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar‐Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. New England Journal of Medicine 1999;340(1):9‐13. - PubMed
Leeda 1998
    1. Leeda M, Riyazi N, Vries J, Jakobs C, Geijn HP, Dekker GA. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. American Journal of Obstetrics and Gynecology 1998;179:135‐9. - PubMed
Lindoff 1997
    1. Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with a reduced response to activated protein c. American Journal of Obstetrics and Gynecology 1997;176(2):457‐60. - PubMed
Nagy 1998
    1. Nagy B, Toth T, Rigo JJ, Karadi I, Romics L, Papp Z. Detection of factor v leiden mutation in severe pre‐eclamptic Hungarian women. Clinical Genetics 1998;53(6):478‐81. - PubMed
Owen 1997
    1. Owen EP, Human L, Carolissen AA, Harley EH, Odendaal HJ. Hyperhomocysteinemia‐‐a risk factor for abruptio placentae. Journal of Inherited Metabolic Disease 1997;20(3):359‐62. - PubMed
Powers 1998
    1. Powers RW, Evans RW, Majors AK, Ojimba JI, Ness RB, Crombleholme WR, et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. American Journal of Obstetrics and Gynecology 1998;179(6 Pt 1):1605‐11. - PubMed
Preston 1996
    1. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348(9032):913‐6. - PubMed
Rajkovic 1997
    1. Rajkovic A, Catalano PM, Manilow MR. Elevated homocysteine levels with preeclampsia. Obstetrics and Gynecology 1997;90:168‐71. - PubMed
Riyazi 1998
    1. Riyazi N, Leeda M, Vries JI, Huijgens PC, Geijn HP, Dekker GA. Low‐molecular‐weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. European Journal of Obstetrics, Gynecology and Reproductive Biology 1998;80(1):49‐54. - PubMed
Rotmensch 1997
    1. Rotmensch S, Liberati M, Mittlemann M, Ben‐Rafael Z. Activated protein c resistance and adverse pregnancy outcome. American Journal of Obstetrics and Gynecology 1997;177(1):170‐3. - PubMed
Sohda 1997
    1. Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate reductase polymorphism and pre‐eclampsia. Journal of Medical Genetics 1997;34(6):525‐6. - PMC - PubMed
Wiener‐Megnagi 1998
    1. Wiener‐Megnagi Z, Ben‐Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae. American Journal of Obstetrics and Gynecology 1998;179(6 Pt 1):1565‐7. - PubMed

Publication types